Publications, Pharmaceutical

Evaluation of Albuterol Sulfate with Low Global Warming Potential Propellants

Reformulating widely used inhaled medications with propellants with a lower global warming potential is an important strategy for improving the sustainability of respiratory therapies.

This paper presents experimental data for a reformulated propellant-only formulation of albuterol sulfate in HFA-152a, a relatively low global warming potential propellant. Aerodynamic particle size distribution data were generated and used to predict regional deposition of the albuterol sulfate. Drug absorption was predicted using a pharmacokinetic model. The results demonstrate the feasibility of producing a stable pressurized metered dose inhaler formulation of albuterol sulfate using HFA-152a. Central deposition behavior was observed to be comparable to a current commercial product (Ventolin).

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 19
Back To Top